We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Bioengineered Jellyfish Provides Insights into Next-Generation Heart Disease Treatments

By LabMedica International staff writers
Posted on 15 Aug 2012
Researchers have successfully tissue-engineered a jellyfish using a mix of silicone polymer and rat-heart cells. More...
Scientists believe this discovery takes them a step closer to understanding how to reverse-engineer entire organs and finding novel treatments for patients with heart damage and failure.

The engineered, 1 cm-long jellyfish is comprised of a membrane with eight arm-like appendages. Within the membrane, rat heart-muscle cells were placed in a specific pattern to promote self-organization and accurately resemble the muscular architecture of a jellyfish. After placing the artificial jellyfish, named Medusoid, in a salty fluid capable of conducting electrical currents, researchers were able to trigger muscle contraction of the membrane by oscillating the voltage in the fluid. As a result of the muscular contractions, vortices (ring-shaped whirling masses of water) were created beneath the organism, allowing it to propel itself forward. This muscular-pump mechanism utilized by the jellyfish for locomotion is equivalent to that of the beating human heart.

Yearly, approximately one million people in the United States die of heart disease, accounting for 42% of the total number of deaths. The US cardiovascular devices market, a USD 15 billion industry forecasted to grow at a compound annual growth rate (CAGR) of 3.1%, represents 11% of the overall medical devices market. The market is driven by the aging population, the increased incidence rate of the disease and the scientific and technological advancements made in the field. These factors contribute to an unmet need in the market to find new and better treatments, according to healthcare market research company, GlobalData (London, UK).

The most common type of heart disease in the United States is coronary artery disease (CAD), characterized by an accumulation of plaque in the coronary arteries. Overtime, this leads to narrowing of the arteries and prevents adequate blood flow to the heart. The disorder can be diagnosed using tests such as an electrocardiogram (ECG), echocardiogram, cardiac catheterization, and coronary angiogram. Treatment for heart disease is tailored for each patient and can vary from drug therapy, monitoring and daily testing to surgical procedures and the implantation of biomedical devices such as stents and pacemakers to regulate cardiac activity.

These temporary treatment options consist of intervention via a substance or medical device. While biomedical devices and medical drugs are tested for safety and biocompatibility, long-term effects such as thrombosis and adverse reactions can occur. Moreover, biomedical devices that are implanted into the patient need to be replaced as they degrade overtime. Innovative solutions need to be designed to address these issues and improve the quality and delivery of healthcare. This study, conducted by investigators from Harvard University(Cambridge, MA, USA) and the California Institute of Technology (Caltech; Pasadena, CA, USA), presents a move in a different direction for scientists in the future to gather cells from one organism and redesign them to create tissue-engineered organs/systems such as heart pacemakers. The current US market for pacemakers is valued at USD 1.6 billion. A tissue-engineered and efficacious “biological heart pacemaker” that would be more biocompatible than a traditional pacemaker and would not require battery power could be beneficial, given the need to develop safe and effective treatments in this market, according to GlobalData.

While bioengineering organs and pacemakers are challenging from a development and regulatory standpoint, the immediate benefits include using the artificial jellyfish as a research model for preclinical testing of new medical heart disease drugs. Harvard’s Dr. Kevin Kit Parker said, “I could put your drug in the jellyfish and tell you if it’s going to work.”

The study findings also revealed that vortex formations generated by the engineered jellyfish are similar to the blood flow patterns entering the left ventricle of the heart. Studying the vortex patterns can provide more data about cardiac health and enable scientists to obtain a deeper understanding of the cardiovascular flow network and mechanisms.

Related Links:

Harvard University
California Institute of Technology
GlobalData



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Specimen Radiography System
TrueView 200 Pro
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The Shield test looks for this cancerous DNA to identify signals associated with colorectal cancer (Photo courtesy of Shutterstock)

Blood Tests Show Potential for Colorectal Cancer Detection

Colorectal cancer remains the second leading cause of cancer-related deaths in the United States, yet many individuals miss screening due to fear, limited access, or the burdens of test preparation.... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.